CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

-  Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products -

REHOVOT, Israel, Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market.